Results for førstegangsbehandlede translation from Danish to English

cytogene analyser hos førstegangsbehandlede b-cll patienter:
29 cytogenetic analyses in first line b-cll patients:

undersøgelse af progressionsfri overlevelse hos førstegangsbehandlede (efter behandlingsgruppe)
progression free survival in first line study (by treatment group)

der blev ikke observeret nogen lægemiddelbaserede bivirkninger i form af pancytopeni/knoglemarvshypoplasi hos førstegangsbehandlede patienter behandlet med mabcampath.
no adverse drug reactions of pancytopenia/marrow hypoplasia were observed in first-line patients treated with mabcampath.

i undersøgelserne af førstegangsbehandlede og tidligere behandlede patienter observeredes ingen væsentlige forskelle i sikkerhed og effektivitet relateret til alder.databasernes størrelse er dog begrænset.
in the studies in first line and previously treated patients no substantial differences in safety and efficacy related to age were observed; however the sizes of the databases are limited.

i tilgængelige data fra førstegangsbehandlede patienter behandlet med mabcampath, observeredes intet tab af cd52-ekspression omkring tidspunktet for sygdomsprogression eller død.
in data available from first line patients treated with mabcampath, loss of cd52 expression was not observed around the time of disease progression or death.

cirka 97% af de førstegangsbehandlede patienter oplevede bivirkninger; og de hyppigst rapporterede reaktioner hos førstegangsbehandlede patienter forekom i reglen i de første uger af behandlingen.
approximately 97% of first-line patients experienced adverse reactions; the most commonly reported reactions in first line patients usually occurred during the first week of therapy.

hos førstegangsbehandlede patienter behandlet med enten campath eller chlorambucil var der 21 patienter med 17 q deletion, 54 patienter med 11 q deletion, 34 patienter med trisomi 12, 51 patienter med normal karyotype og 67 patienter med kun 13 q deletion.
in first line patients, treated with either campath or chlorambucil, there were there were 21 patients with the 17p deletion, 54 patients with 11q deletion, 34 patients with trisomy 12, 51 patients with normal karyotype and 67 patients with sole 13q deletion.

blandt de førstegangsbehandlede patienter er følgende alvorlige bivirkninger rapporteret under behandlingsperioden med grade 3 sværhedsgrad:cmv-tilfælde (infektion/viræmi) og pneumoni rapporteredes hyppigt; følgende rapporteredes som mindre almindeligt: bronkopneumoni, tinea corporis, genital candidiasis, sepsis, tuberkulose og urinvejsinfektion.
among first-line patients during the on treatment period, the following adrs were reported with grade 3 severity; cmv events (infection/viraemia) and pneumonia were reported commonly; the following were reported uncommonly; bronchopneumonia, body tinea, genital candidiasis, sepsis, tuberculosis and urinary tract infection.